Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

Diabetes, Obesity and Metabolism

Volumn 2, Issue 6, 2000, Pages 355-362

  Gentile, Sandro ^a   Turco, S ^a   Guarino, G ^b   Sasso, C F ^a   Amodio, M ^a   Magliano, P ^a   Salvatore, T ^a   Corigliano, G ^a   Agrusta, M ^d   De Simone, G ^c   Gaeta, I ^c   Oliviero, B ^a   Torella, R ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Diabetes Unit of the Italian Association for Diabetes (AID)   (Italy)

^d Diabetes and Endocrinology Unit of ASL1   (Italy)

Author keywords

Coronary artery disease risk; HMG CoA reductase inhibitors; Hypercolesterolaemia; Type 2 diabetes mellitus

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIETARY INTAKE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE; VERTIGO;

EID: 0034522396     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00106.x     Document Type: Article

References (50)

1. Diabetes and cardiovascular risk factors in the Framingham Study
2. The Whitehall Study: Comparative mortality rates and indices of risk in diabetes
3. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study
4. Impact of cardivascular risk factors on coronary heart disease and mortality among middle aged diabetic men: A general population study
5. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
6. Atherosclerosis in diabetes mellitus. Correlation with serum lipid levels, adiposity and serum insulin levels
7. Hypertiglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective study
8. High density and low density lipoproteins and prevalence of vascular disease in diabetes mellitus
9. Association of low HDL and LDL2 cholesterol with coronary heart disease in non-insulin-dependent diabetics
10. Clinical macrovascular disease in Caucasoid diabetic subjects: Logistic regression analysis of risk variables
11. Diabetes blood lipids and the role of obesity in coronary heart disease risk for women: The Framingham study
12. Abnormal concentration of high density lipoproteins in non-insulin-dependent diabetics
13. Plasma lipids and diabetes mellitus in an adult community
14. Serum lipids and lipoproteins in newly diagnosed non-insulin-dependent (type II) diabetic patients, with special reference to factors influencing HDL cholesterol concentrations on coronary heart disease risk Study: Implications for treatment
15. Joint effects of serum triglyceride and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implication for treatment
16. Results and conclusions of the Prospective Cardiovascular Munsen (PROCAM) Study
17. Clinical practice recommendations. Detection and management of lipid disorder in diabetes
18. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
19. Comparative dose efficacy study of atorvastatin, versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
20. Detection and management of lipid disorders in Diabetes
21. Effect of treatment with a hydroxymetylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester activity in patients with NIDDM
22. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes
23. Management of dyslipidemia in NIDDM
24. Atorvastatin, a new HMG-CoA reductase inhibitor, is safe and effective in NIDDM patients with hyperlipidemia
25. Antiatherosclerotic activity of inhibitors of 3-hydrozy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation
26. Estimation of the concentration of ultracentrifuge
27. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics' methodology
28. Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique
29. Measurement of protein with the Boehringg nephelometer: A multicenter evaluation
30. A multiple comparison procedure for comparing several treatments with a control
31. Comparison of properties of four inhibitors of 3-hydrozyl-3-methylglutaryl-coenzume A reductase
32. Hypertriglyceridemia: A contraindication to the use of bile acid binding resins
33. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced resistance
34. Nicotinic acid as therapy for dyslipidemia in NIDDM
35. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus
36. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM
37. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mol/liter (200-399 mg/dl) plus two additional atherosclerotic risk factors
38. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survey Study (4S)
39. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in treatment of primary hyper-cholesterolemia
40. Expanded clinical evaluation of lovastatin (EXCEL) study IV. Additional perspective on the tolerability of lovastatin
41. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors
42. Reduction of HDL-Cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
43. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides
44. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
45. Effects of pravastatin sodium and simvastatin on plasma fibrinogen and blood reology in type II hypercholesterolemia
46. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen in patienys with primary hypercholesterolemia
47. Effect of atorvastatin on plasma fibrinogen
48. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
49. A multicenter, double-blind, one-year study comparison safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
50. The effect of pravastatin on coronary events after myocardial infarction in patients with average choletserol levels